Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16333914 | 0.98 | KEAP1 (0.56) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL14320570 | 0.84 | DYRK1A (0.71) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL12181628 | 0.76 | DYRK1A (0.57) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL14826052 | 0.76 | DYRK1A (0.85) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL15376869 | 0.75 | RAB9A (0.56) | KEAP1DYRK1AMAOBHDAC1MCHR1 | |
| SCHEMBL19599268 | 0.74 | DYRK1A (0.53) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL12850063 | 0.74 | DYRK1A (0.53) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL408627 | 0.74 | DYRK1A (0.53) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL21230274 | 0.74 | DYRK1A (0.53) | KEAP1DYRK1AKMT2AMEN1CYP1A2 | |
| SCHEMBL1832813 | 0.74 | DYRK1A (0.53) | KEAP1DYRK1AKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285947-A | Low-temperature curing polyimide precursor solution and preparation method thereof | 北京化工大学常州先进材料研究院 | 2025-01-10 | — | — | CN | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-0930062-A1 | Compositions containing imidazo-pyridine derivatives for dying keratinous fibres and process | L'OREAL (FR) | 1999-07-21 | — | — | EP | claimed |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| CN-120957950-A | Anthraquinone/reductive graphene oxide mediator film and preparation method and application thereof | 厦门理工学院 | 2025-11-14 | — | — | CN | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025057074-A1 | N-ARYL BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-5980585-A | NONTOXIC; HAIR DYE | L'OREAL (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0930062-A1 | Compositions containing imidazo-pyridine derivatives for dying keratinous fibres and process | L'OREAL (FR) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | KEAP1 252/4885DYRK1A 1850/4885KMT2A 148/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | KEAP1 1071/4885DYRK1A 4302/4885KMT2A 1432/4885 |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, XDH, SLC10A1 | KEAP1 1193/4885DYRK1A 3271/4885KMT2A 3925/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | KEAP1 1071/4885DYRK1A 4302/4885KMT2A 1432/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | KEAP1 908/4885DYRK1A 4231/4885KMT2A 723/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | KEAP1 2612/4885DYRK1A 1291/4885KMT2A 1171/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | KEAP1 1071/4885DYRK1A 4302/4885KMT2A 1432/4885 |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KEAP1 1284/4885DYRK1A 3064/4885KMT2A 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.